Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

Fig. 3

Efficacy of tirzepatide in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1 to 5; [15,16,17,18,19]) clinical trials, all according to the treatment estimand (SURPASS 1–5) or by Bayesian modified intention-to-treat analysis without considering data acquired post-rescue (GPWB). The upper row of panels depicts effects on HbA1c (reduction vs. baseline). The lower row of panels shows effects on body weight (reduction vs. baseline). Asterisks (*) indicate a significant difference (p < 0.05) vs. the respective comparator. Comparators were placebo and dulaglutide (1.5 mg per week) in phase 2 (GPGB), placebo (grey; SURPASS-1 and -5), semaglutide 1.0 mg (orange; SURPASS-2), basal insulin degludec (darker brown; SURPASS-3) and basal insulin glargine U100 (lighter brown; SURPASS-4). Patient numbers per arm are presented in the bottom of the lower panels

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840